Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
1. The time-course of the effect of clofibrate (CFB), bezafibrate (BFB) and gemfibrozil (GFB) on lipid plasma levels and palmitoyl-CoA hydrolase and synthetase activities, as well as the correlations with the peroxisomal proliferation phenomenon have been studied in male Sprague-Dawley rats. 2. The administration of the three drugs caused a significant reduction in body weight gain, accompanied with a paradoxical increase in food intake in groups treated with BFB and GFB. 3. Drug treatment produced gross hepatomegaly and increase in peroxisomal beta-oxidation, and these parameters were strongly correlated. The order of potency was BFB > CFB > or = GFB. 4. Both plasma cholesterol (BFB approximately CFB > GFB) and triglyceride (BFB approximately GFB > CFB) levels were reduced in treated animals. There was an inverse correlation between these parameters and peroxisomal beta-oxidation, although the peroxisomal proliferation seemed to explain only a small part of the hypolipidemic effect observed. 5. Cytosolic and microsomal (but not mitochondrial) palmitoyl-CoA hydrolase activities were increased by the three drugs (BFB > CFB > GFB), probably by inducing the hydrolase I isoform, which is insensitive to inhibition by fibrates in vitro. The increased hydrolase activities were directly and strongly correlated with peroxisomal beta-oxidation. 6. Palmitoyl-CoA synthetase activity was also increased by the treatment with fibrates (BFB > CFB > GFB), probably as a consequence of the enhancement of hydrolase activities. 7. Some of the effects of fibrate treatment can be explained, at least in part, in terms of peroxisomal induction and caution should be exercised in the extrapolation of these results to species, such as man,that are insensitive to peroxisomal proliferation.
Alegret
M
M
Dept. Farmacología y Química Terapeutica, Facultad de Farmacia, Núcleo Universitario de Pedralbes, Barcelona, Spain.
Ferrando
R
R
Vázquez
M
M
Adzet
T
T
Merlos
M
M
Laguna
J C
JC
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology; D003066:Coenzyme A Ligases / Q000097:blood*; D004032:Diet; D015248:Gemfibrozil / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008830:Microbodies / Q000187:drug effects / Q000502:physiology*; D009929:Organ Size / Q000187:drug effects; D010170:Palmitoyl-CoA Hydrolase / Q000097:blood*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012097:Repressor Proteins; D029701:Saccharomyces cerevisiae Proteins; D014280:Triglycerides / Q000097:blood; D000098859:Long-Chain-Fatty-Acid-CoA Ligase
D000960:Hypolipidemic Agents; D008055:Lipids; D012097:Repressor Proteins; D029701:Saccharomyces cerevisiae Proteins; D014280:Triglycerides; D002784:Cholesterol; D010170:Palmitoyl-CoA Hydrolase; D003066:Coenzyme A Ligases; C090799:FAA2 protein, S cerevisiae; D000098859:Long-Chain-Fatty-Acid-CoA Ligase; D002994:Clofibrate; D015248:Gemfibrozil; D001629:Bezafibrate